Dynamine (Methylliberine)
Dynamine is a fast stimulant add-on, usually discussed around 50-150 mg, with Cintineo 2022 testing methylliberine alongside caffeine and theacrine in tactical personnel. It may feel strong, but caffeine interaction and thin independent evidence limit default use.
Dynamine (Methylliberine) scored 4.9 / 10 (⚖️ Neutral) on the BioHarmony scale as a Substance → Stimulant / Methylxanthine.
What It Is
Dynamine (Methylliberine) scores 4.9/10 because its strongest case is acute energy, vigilance, and reaction-time support, with weaker support outside that lane. The best read is practical and narrow: match the intervention to healthy users seeking short-duration stimulant effects without treating it as a caffeine replacement proof.
The main evidence anchor is Cintineo et al. 2022. Feduccia et al. 2020 adds important context, while Taylor et al. 2020 helps define the safety, sourcing, or regulatory caveat that keeps the score from moving higher.
The key caveat is that the human evidence is short term, commercially concentrated, and too thin for chronic-use confidence. This report treats Dynamine as a candidate for specific use cases, not a general wellness shortcut.
Terminology
AMPA: A glutamate receptor family involved in fast excitatory signaling. - CYP1A2: A liver enzyme relevant to caffeine and xanthine metabolism. - ER Stress: Endoplasmic-reticulum stress, a cellular protein-folding stress pathway. - MAO-B: Monoamine oxidase B, an enzyme that breaks down dopamine-related monoamines. - NOAEL: No observed adverse effect level in toxicology work.
UDCA: Ursodeoxycholic acid, the unconjugated parent bile acid of TUDCA. - WADA: World Anti-Doping Agency, relevant for athlete prohibited-list risk.
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Oral | Capsule, powder, tablet, or food form depending on intervention | 50-150 mg/day in commercial stimulant products | 50-150 mg/day in commercial stimulant products |
Protocols
Conservative research comparison Mixed
- Dose
- 50-150 mg
- Frequency
- As studied or label-directed, with outcome tracking
- Duration
- Single session to 12 weeks depending on endpoint
Research-assistance framing only; avoid unsupervised escalation.
How this score is calculated →
Upside contribution: 1.15
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 2.2 | 0.550 | |
| Breadth of Benefits | 15% | 2.0 | 0.300 | |
| Evidence Quality | 25% | 1.7 | 0.425 | |
| Speed of Onset | 10% | 3.4 | 0.340 | |
| Durability | 10% | 1.7 | 0.170 | |
| Bioindividuality Upside | 15% | 2.4 | 0.360 | |
| Total | 2.145 |
Upside Rationale
Dynamine (Methylliberine) scores 4.9/10 because its upside is concentrated in acute energy, vigilance, and reaction-time support. The clearest anchor is a tactical-personnel trial plus short-term safety papers, so the rating rewards the specific use cases while staying conservative about claims beyond them.
Efficacy (3.1/5.0): Dynamine earns this efficacy score because the best signals map to acute energy, vigilance, and reaction-time support. Cintineo et al. 2022 is the main anchor, while Feduccia et al. 2020 helps define where the signal remains preliminary.
Breadth of Benefits (2.5/5.0): Dynamine has limited breadth outside its core lane. The report gives more credit where the evidence matches healthy users seeking short-duration stimulant effects without treating it as a caffeine replacement proof, and less where endpoints drift into unrelated systems.
Evidence Quality (2.2/5.0): Dynamine evidence quality is constrained by sample size, age of the literature, sponsor concentration, or indirect endpoints. Cintineo et al. 2022 and Taylor et al. 2020 keep the score useful without overstating certainty.
Speed of Onset (4.3/5.0): Dynamine can produce faster feedback when the intended effect is acute attention, energy, sleep timing, digestion, or performance. That speed helps users judge fit, but it does not replace longer safety follow-up.
Durability (2.0/5.0): Dynamine durability is moderate to low when continued dosing, training context, sleep timing, diet, or supply quality drives the result. The score rises only when the benefit can be maintained without chasing dose escalation.
Bioindividuality Upside (2.8/5.0): Dynamine has meaningful bioindividuality because baseline need, medications, caffeine response, training status, liver or bile context, sleep pressure, and tolerance can change the outcome. Feduccia et al. 2020 is useful for defining that context.
Downside contribution: 1.34 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 2.2 | 0.660 | |
| Side Effect Profile | 15% | 2.2 | 0.330 | |
| Financial Cost | 5% | 2.2 | 0.110 | |
| Time/Effort Burden | 5% | 1.5 | 0.075 | |
| Opportunity Cost | 5% | 2.1 | 0.105 | |
| Dependency / Withdrawal | 15% | 2.1 | 0.315 | |
| Reversibility | 25% | 1.6 | 0.400 | |
| Total | 1.995 | |||
| Harm subtotal × 1.4 | 2.387 | |||
| Opportunity subtotal × 1.0 | 0.290 | |||
| Combined downside | 2.677 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 1.337 |
Downside Rationale
Dynamine (Methylliberine) downside is driven by the human evidence is short term, commercially concentrated, and too thin for chronic-use confidence. The risk score is highest where user selection, product quality, stimulant load, medical context, or regulation can change the expected result.
Safety (2.6/5.0): Dynamine safety concerns are manageable for some users and unacceptable for others depending on dose, diagnosis, medication use, and source quality. Feduccia et al. 2020 is the main safety anchor for this dimension.
Side Effects (2.7/5.0): Dynamine side effects matter because the likely use cases often depend on subjective feel, stimulation, digestion, sleep, or skin response. Cintineo et al. 2022 helps frame expected benefits against tolerability.
Interaction Risk (2.5/5.0): Dynamine interaction risk rises when users combine it with stimulants, sedatives, anticoagulants, liver-active agents, training stress, or disease-specific treatment. The report keeps this dimension separate from general safety.
Supply (2.6/5.0): Dynamine supply risk reflects labeling accuracy, adulteration, ingredient identity, and whether the market is supplement, prescription, peptide, or gray-market dominated. Taylor et al. 2020 is especially relevant when product trust is part of the risk.
Cost (2.2/5.0): Dynamine cost risk is not only price per serving. It also includes the cost of chasing weak evidence, lab testing, medical monitoring, or replacing simpler options such as sleep, diet, training, or caffeine management.
Regulatory (2.4/5.0): Dynamine regulatory risk depends on whether the compound is a normal food, a dietary supplement ingredient, a drug, a sport-restricted substance, or a research peptide. This can be the deciding downside for athletes and cautious users.
Bioindividuality Downside (2.9/5.0): Dynamine bioindividuality downside is meaningful because personal risk can swing with anxiety, sleep timing, pregnancy, age, liver or kidney status, sport testing, CYP metabolism, and baseline deficiency or excess.
Verdict
Dynamine is a conditional research candidate rather than a universal recommendation. The score is most favorable when the reader's target matches the highest use-case scores, the product source is credible, and the reader can track a concrete outcome before and after use. The score is least favorable when Dynamine is used to chase vague optimization, replace higher-certainty basics, or stack with overlapping compounds without a clear reason.
✅ Best for: Short stimulant trials where caffeine co-use, sleep timing, and limited independent replication are explicit constraints. Dynamine makes the most sense when the reader can define the target outcome in advance, compare Dynamine with the related reports above, and stop quickly if the result is poor.
❌ Avoid if: Avoid Dynamine when legal status, athlete testing, medication conflicts, allergy risk, organ disease, pregnancy questions, stimulant sensitivity, or poor sourcing changes the risk picture. Avoid using Dynamine as a substitute for sleep, nutrition, training, medical care, or well-supported alternatives.
Use Case Breakdown
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Energy / Fatigue: 5.5/10
Score: 5.5/10Dynamine scores 5.5/10 for energy because the most plausible benefit is acute perceived energy or stimulant-like activation. The strongest support comes from Cintineo H. et al. 2022, but the practical rating stays bounded by study size, replication, and how directly the endpoint maps to healthy-user goals. For readers, Dynamine is best interpreted as a focused use-case candidate, not a broad proof of benefit across unrelated systems. The score would move higher with independent replication, longer follow-up, and cleaner head-to-head comparisons against common alternatives.
Cognition / Focus: 5.0/10
Score: 5.0/10Dynamine scores 5.0/10 for cognition focus because the human or mechanistic literature points most directly at attention, focus, or cognitive-task performance. The strongest support comes from Cintineo H. et al. 2022, but the practical rating stays bounded by study size, replication, and how directly the endpoint maps to healthy-user goals. For readers, Dynamine is best interpreted as a focused use-case candidate, not a broad proof of benefit across unrelated systems. The score would move higher with independent replication, longer follow-up, and cleaner head-to-head comparisons against common alternatives.
Reaction Time / Coordination: 5.0/10
Score: 5.0/10Dynamine scores 5.0/10 for reaction time because the reported benefit is most likely to show up on short-latency cognitive or performance tasks. The strongest support comes from Cintineo H. et al. 2022, but the practical rating stays bounded by study size, replication, and how directly the endpoint maps to healthy-user goals. For readers, Dynamine is best interpreted as a focused use-case candidate, not a broad proof of benefit across unrelated systems. The score would move higher with independent replication, longer follow-up, and cleaner head-to-head comparisons against common alternatives.
Frequently Asked Questions
What does Dynamine actually do?
Dynamine mainly acts through the biology described in this report, and the best concise source is Cintineo H. et al. 2022. Dynamine should be read as a research-assistance topic rather than a treatment recommendation. That is why the score separates plausible pathways from proven user value.
How much Dynamine is typically used?
Dynamine is usually discussed around 50-150 mg/day in commercial stimulant products, but dosing depends on context, product quality, and clinician constraints. This report lists research and anecdotal ranges for comparison only. Dynamine should not be stacked casually with overlapping drugs or stimulants, and higher doses should be treated as a separate risk decision. The safest reading is to compare published ranges with the label and personal tolerance.
What does the human evidence show for Dynamine?
Dynamine has an evidence profile led by Cintineo H. et al. 2022 and the other sources in the evidence table. Dynamine receives credit when human outcomes exist and loses credit when the work is small, industry-concentrated, disease-specific, or not independently replicated. That is why a popular community use can still receive a modest score when the direct clinical literature is thin.
Is Dynamine safe long term?
Dynamine looks safer when dose, source quality, medication conflicts, and stop criteria are handled conservatively. The long-term safety answer is weaker when human follow-up is short, when products are unapproved drugs, or when stimulant effects can affect sleep and cardiovascular comfort. Dynamine earns a better safety rating only where the evidence base includes ordinary-use tolerability and clear reversibility.
Who should avoid Dynamine?
Dynamine should be avoided by readers with relevant medication conflicts, pregnancy questions, severe organ disease, allergy risk, or athlete testing exposure when those concerns apply. Dynamine also deserves caution when the supply chain is unclear or when the main goal could be met by better-studied options. The report frames these as research guardrails, not individualized medical instructions.
How fast does Dynamine work?
Dynamine may feel acute when the mechanism is stimulant-like, but disease or recovery outcomes usually need longer observation. The timeline in this report separates same-day subjective effects from delayed biomarkers and functional changes. Dynamine should be judged with a preplanned outcome, because vague improvement tracking can make short-lived arousal feel more useful than it is.
How is Dynamine different from nearby alternatives?
Dynamine differs from nearby alternatives by mechanism, evidence quality, legality, and product reliability. The related reports linked in the verdict help compare Dynamine with better-known options before treating the category as interchangeable. A close alternative may have lower subjective novelty but better replication, easier sourcing, or fewer interaction problems, which matters for the final score.
What would make the Dynamine score change?
Dynamine would score higher with larger independent trials, longer safety follow-up, clearer dosing, and direct evidence for the main use cases. Dynamine would score lower if safety signals strengthen, product quality worsens, or better alternatives cover the same goal with less uncertainty. The score is therefore a snapshot of current evidence, not a permanent verdict.
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
Dynamine could move meaningfully if the evidence base changes because several current uncertainties are fixable. Independent trials could raise confidence, longer follow-up could clarify safety, and better product testing could reduce sourcing concern. Dynamine could also fall if larger studies fail to replicate the small positive findings, if regulatory scrutiny increases, or if real-world users report a pattern of sleep, mood, digestive, or cardiovascular problems. The scenarios below show how the same intervention can move across tiers without changing the scoring method, simply by improving or weakening the underlying facts.
| Scenario | Likely score |
|---|---|
| Larger independent human trials replicate the best outcome and safety stays clean. | 6.1 / 10 👍 Worth trying |
| Evidence stays mostly small, sponsor-linked, or disease-specific. | 4.9 / 10 ⚖️ Neutral |
| New safety, sourcing, regulatory, or replication concerns appear. | 3.7 / 10 ⚠️ Caution |
BioHarmony Engine v1.0
Key Evidence Sources
- Effects of caffeine, methylliberine, and theacrine on vigilance, marksmanship, and hemodynamic responses in tactical personnel: a double-blind, randomized, placebo-controlled trial. Effects of caffeine, methylliberine, and theacrine on vigilance, marksmanship, and hemodynamic responses in tactical personnel: a double-bli
- A Toxicological Evaluation of Methylliberine (Dynamine®). Reviewed in 2026 for study design and population fit; supports a specific endpoint rather than broad wellness claims.
- Safety of Short-Term Supplementation with Methylliberine (Dynamine. Reviewed in 2026 as clinical or mechanistic background; sample, year, and endpoint directness shape the confidence rating.
- Wikidata entity Q108603652. Reviewed in 2026 for citation integrity; useful for mechanism or outcome context but not treated as universal proof.
- Dietary Supplements. Reviewed in 2026 as a primary evidence source; study design, year, and endpoint context are used to bound the report claim.
- ClinicalTrials registry. Reviewed in 2026 for study design and population fit; supports a specific endpoint rather than broad wellness claims.
- PubChem compound database. Reviewed in 2026 as clinical or mechanistic background; sample, year, and endpoint directness shape the confidence rating.
- World Anti-Doping Agency prohibited list. Reviewed in 2026 for citation integrity; useful for mechanism or outcome context but not treated as universal proof.
- NIH Office of Dietary Supplements. Reviewed in 2026 as a primary evidence source; study design, year, and endpoint context are used to bound the report claim.
- MedlinePlus herbs and supplements. Reviewed in 2026 for study design and population fit; supports a specific endpoint rather than broad wellness claims.
Holistic Evidence Profile
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Low
Citations: Cintineo 2022: Effects of caffeine, methylliberine, and theacrine on vigilance, marksmanship, and hemodynamic responses in tactical personnel: a double-blind, randomized, placebo-controlled trial.
Pre-RCT-Era Pharmacology and Use
Citations: Effects of caffeine, methylliberine, and theacrine on vigilance, ma..., A Toxicological Evaluation of Methylliberine, Safety of Short-Term Supplementation with Methylliberine
Traditional Medicine Systems
Citations: Effects of caffeine, methylliberine, and theacrine on vigilance, ma..., A Toxicological Evaluation of Methylliberine, Safety of Short-Term Supplementation with Methylliberine
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- Blood Pressure Baseline (pre-protocol)
- Resting Heart Rate During | Expected Watch
- Sleep Duration During | Expected Down
Pulse Dimensions to Watch
- Energy During | Expected Up | Primary
- Drive During | Expected Up | Primary
- Sleep During | Expected Watch | Secondary
Subjective Signals (Daily Voice Card)
- Stimulant Smoothness Scale 1-5 | During | Expected Up
- Jitters Scale 1-5 | During | Expected Watch
Red Flags: Stop and Consult
- Palpitations, chest pain, or panic
- High-dose caffeine co-use
Other interventions for Energy
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–3.6, Caution 3.7–4.7, Neutral 4.8–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–7.9, Top-tier 8.0+.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 1.145 − 1.337 = -0.192
Formula v0.5 maps EV = 0 to score 5.0. Above neutral, 1 EV point equals 1 score point. Below neutral, 1 EV point equals about 0.71 score points, so EV = −7 reaches 0.0 while EV = +5 reaches 10.0. Both sides use the full 5-point half-scale.
Score = 5 + (-0.192 / 7) × 5 = 4.9 / 10
